RecruitingNCT05919511

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Sponsor

Incyte Corporation

Enrollment

1,500 participants

Start Date

Aug 1, 2023

Study Type

OBSERVATIONAL

Conditions

cGVHD

Summary

The purpose of this prospective observational study is to collect data from participants who have recently had an allogenic Stem Cell Transplant(alloSCT) and are at risk of Chronic Graft Versus Host Disease(cGVHD)

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Non-Interventional for people with cgvhd. The study is currently recruiting participants at 32 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNon-Interventional

This is an observational study

Locations(32)

University of Alabama Birmingham

Birmingham, Alabama, United States

Mayo Clinic Arizona

Phoenix, Arizona, United States

City of Hope

Duarte, California, United States

USC Norris Comprehensive Cancer Center

Los Angeles, California, United States

University of Colorado

Aurora, Colorado, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

AdventHealth Orlando

Orlando, Florida, United States

Moffit Cancer Center

Orlando, Florida, United States

Emory University

Atlanta, Georgia, United States

Georgia Cancer Center

Augusta, Georgia, United States

Northwestern University

Chicago, Illinois, United States

Rush University Medical Group

Chicago, Illinois, United States

The University of Chicago

Chicago, Illinois, United States

Loyola University Medical Center

Maywood, Illinois, United States

The University of Kansas Clinical Research Center

Fairway, Kansas, United States

Tulane Cancer Center

New Orleans, Louisiana, United States

University of Maryland Medical Center

Baltimore, Maryland, United States

Massachusetts Cancer Research Center

Boston, Massachusetts, United States

Corewell Health

Grand Rapids, Michigan, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

The Ohio State University

Columbus, Ohio, United States

Oregon Health Sciences University

Portland, Oregon, United States

Geisinger Health Systems

Danville, Pennsylvania, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Texas Oncology-Baylor Charles A. Sammons Cancer Center

Dallas, Texas, United States

University of Utah, Huntsman Cancer Institute

Salt Lake City, Utah, United States

Fred Hutchinson Cancer Research Center

Seattle, Washington, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05919511

Related Trials

Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease

NCT066637223 locations

Safety and Efficacy of Iguratimod in the Treatment of Chronic GVHD

NCT062446281 location

A Clinical Study Evaluating the Safety and Efficacy of GT729 Universal Cell Injection in the Treatment of Refractory or Relapsed Chronic Graft-versus-host Disease (cGVHD)

NCT072532591 location

BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation

NCT072460311 location

Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2

NCT069201991 location